

FROM SUGHRUE MION PLLC DC

(TUE) 1.13'04 16:22/ST. 16:21/NO. 4260759902 P 1

2100 Pennsylvania Avenue, NW
Washington, DC 20037-3213

T 202.293.7060
F 202.293.7860

www.sughrue.com



FAX

Date January 13, 2004

To Zohreh A. FAY

Of U.S. Patent and Trademark Office

Fax 703.746.3175

From J. Timothy Meigs

Subject ***Copy of Amendment filed April 29, 2003 in re U.S. Appln. 09/601,505***

Our Ref Q60247

Pages 6
(including cover sheet)

Please call attention to problems with this transmission by return fax or telephone. Thank you.

THE INFORMATION CONTAINED IN THIS COMMUNICATION IS CONFIDENTIAL, MAY BE ATTORNEY-CLIENT PRIVILEGED, AND IS INTENDED ONLY FOR THE USE OF THE ADDRESSEE. UNAUTHORIZED USE, DISCLOSURE OR COPYING IS STRICTLY PROHIBITED AND MAY BE UNLAWFUL. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US.

Dear Ms. Fay:

Per your conversation with Mr. Meigs, I am enclosing a copy of our response to the Office Action dated January 29, 2003. Our response was filed on April 29, 2003.

Jeanine Stewart
secretary to J. Timothy Meigs

24

FILING RECEIPT
PLEASE DATE STAMP AND RETURN TO US - BOX 235X

In re application of

Masamichi OKADA, et al.

Appln. No.: 09/601,505

Confirmation No.: 2988

Filed: August 2, 2000

For: REMEDIES FOR CEREBRAL INFARCTION

PAPER(S) FILED ENTITLED:

1. AMENDMENT UNDER 37 C.F.R. §1.111

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE




23373

PATENT TRADEMARK OFFICE

DOCKET NO.: Q60247

ATTORNEY/SEC: SJM/DXH

Date Filed: April 29, 2003



PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q60247

Masamichi OKADA, et al.

Appln. No.: 09/601,505

Group Art Unit: 1614

Confirmation No.: 2988

Examiner: Zohreh A. Fay

Filed: August 02, 2000

For: REMEDIES FOR CEREBRAL INFARCTION

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
Washington, D.C. 20231

FILED
APR 29 2003

Sir:

In response to the Office Action dated January 29, 2003, please amend the above-identified application as follows:

AMENDMENT UNDER 37 C.F.R. §1.111
U.S. Appl. No. 09/601,505

Q60247

IN THE CLAIMS:

Please enter the following amended claims:

5. (canceled).
6. (previously amended) A method for treatment of a mammal afflicted with acute stage ischemic stroke, said method comprising the step of administering a compound having mGluR1 antagonism to said mammal.
7. (previously amended) The method according to claim 6, wherein said compound is 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzoimidazole-2-carboxamide dihydrochloride.
8. (previously amended) The method according to claim 6, wherein said compound does not have an agonist or antagonist effect on mGluR2, mGluR3, mGluR4, mGluR6 or mGluR7.

AMENDMENT UNDER 37 C.F.R. §1.111
U.S. Appln. No. 09/601,505

Q60247

REMARKS

Claims 5-8 are all the claims pending in the application; claims 6-8 are allowed; claim 5 is rejected.

Claim 5 has now been canceled.

No new matter has been added. Entry of the amendment is respectfully requested.

I. Rejection of Claims Under 35 U.S.C. §102(b)

At page 2 of the Office Action, claim 5 is rejected under 35 U.S.C. §102(b) as being anticipated by Japanese Patent Application ("JPA") No. 8-169884.

The Examiner states that the JPA teaches the use of the claimed compounds in a pharmaceutical formulation.

While Applicants disagree with the Examiner's position regarding the disclosure of the JPA and the anticipation of claim 5, to further prosecution of the present application, Applicants include herewith an amendment to the claims such that claim 5 is canceled, thereby making the rejection moot.

In view of the amendment to the claims, Applicants respectfully request reconsideration and withdrawal of this rejection.

II. Conclusion


In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

AMENDMENT UNDER 37 C.F.R. §1.111
U.S. Appl. No. 09/601,505

Q60247

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE



23373

PATENT TRADEMARK OFFICE

Date: April 29, 2003